Senseonics Holdings, which is developing a long-lasting implantable glucose monitor for diabetics, announced terms for its IPO on Tuesday.
The Germantown, MD-based company plans to raise $60 million by offering 18.2 million shares at a price range of $3.10 to $3.50. At the midpoint of the proposed range, Senseonics Holdings would command a fully diluted market value of $341 million.
Senseonics Holdings was founded in 1996. It plans to list on the NYSE MKT under the symbol SENS. Leerink Partners and Canaccord Genuity are the joint bookrunners on the deal. It is expected to price during the week of March 14, 2016.
